1. |
郭義恒, 于改革. 氟伐他汀治療高尿酸血癥腎病的Ⅰ期臨床觀察. 實用雜志, 2008, 22(4): 295-296.
|
2. |
黨群, 王敬, 張瑩. 高尿酸血癥與高血壓發生心血管事件的相關性探討. 中華實用診斷與治療雜志, 2006, 20(7): 505-506.
|
3. |
賈強, 婁姍姍, 孟召, 等. 性別和年齡與高尿酸血癥及代謝綜合征的關系. 中國全科醫師, 2011, 10(8): 567-568.
|
4. |
李加平, 喻巧云. 高尿酸血癥與代謝綜合征的相關性研究. 國際檢驗醫學雜志, 2011, 32(12): 1322-1325.
|
5. |
張秀娟, 辛長貴. 原發性高尿血癥及痛風易感基因研究進展. 中華內分泌代謝雜志, 2011, 27(7): 611-612.
|
6. |
Masbernard A, Giudicelli CP. Ten years’ experience with benzbromarone in the management of gout and hyperuricaemia. S Afr Med, 1981, 59(65): 701-706.
|
7. |
van der Klauw MM, Houtman PM, Stricker BH, et al. Hepatic injury caused by benzbromarone. J Hepatol, 1994, 20(3): 376-379.
|
8. |
Wagayama H, Shiraki K, Sugimoto K, et al. Fatal fulminant hepatic failure associated with benzbromarone. J Hepatol, 2000, 32(5): 874.
|
9. |
Suzuki T, Suzuki T, Kimura M, et al. A case of fulminant hepatitis, possibly caused by benzbromarone. Nippon Shokakibyo Gakkai Zasshi, 2001, 98(4): 421-425.
|
10. |
葉任高, 陸再英. 內科學(第6版). 北京: 人民衛生出版社, 2006: 862.
|
11. |
Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1. The Cochrane Collaboration, 2008.
|
12. |
胡政國, 劉家鐸. 苯溴馬隆與別嘌呤醇治療高尿酸血癥的療效比較. 中國基層醫藥, 2010, 17(18): 2506-2507.
|
13. |
王雪君, 沈建軍. 小劑量苯溴馬隆與別嘌呤醇治療高尿酸血60例療效觀察. 中國現代應用藥學雜志, 2007, 24(4): 337-338.
|
14. |
趙占正, 肖靜, 劉章鎖. 苯溴馬隆與別嘌呤醇治療高尿酸血癥/痛風的療效觀察. 中國誤診學雜志, 2005, 5(2): 281-282.
|
15. |
韓文娟, 錢培玲, 顧詠亮, 等. 苯溴馬隆與別嘌醇治療高尿酸血癥臨床效果對照. 上海醫藥, 2004, 25(10): 468-469.
|
16. |
Reinders MK, Haagsma C, Jansen TL, et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout. Ann Rheum Dis, 2009, 68(6): 892-897.
|
17. |
Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, et al. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis, 1998, 57(9): 545-549.
|